Discover Oncology (Sep 2023)

Identification of galactosamine-(N-acetyl)-6-sulfatase (GALNS) as a novel therapeutic target in progression of nasopharyngeal carcinoma

  • Jin Zhang,
  • Hong Ran,
  • Zhen Wang,
  • Peng Liu,
  • Chenglin Kang,
  • Xianhai Zeng,
  • Shuqi Qiu,
  • Peng Zhang

DOI
https://doi.org/10.1007/s12672-023-00782-4
Journal volume & issue
Vol. 14, no. 1
pp. 1 – 11

Abstract

Read online

Abstract Nasopharyngeal carcinoma (NPC) is a commonly diagnosed malignancy in southern China and southeast Asia. Previous studies have identified galactosamine-(N-acetyl)-6-sulfatase (GALNS) as a potential biomarker for multiple cancers. However, it is unknown whether GALNS plays a role in NPC development, and the underlying mechanisms remain unclear. In this study, we found that GALNS is overexpressed in NPC cell lines and tissues compared to the normal nasopharyngeal counterparts. Knocking down GALNS expression in the NPC cells significantly decreased their proliferation in vitro, and inhibited xenograft growth in a mouse model. Mechanistically, the anti-proliferative effect of GALNS silencing was the result of autophagy induction via the inhibition of PI3K–AKT–mTOR signaling pathway. Taken together, GALNS drives the progression of NPC via PI3K–AKT–mTOR signaling-mediated autophagy, and is therefore a promising therapeutic target.

Keywords